Indaptus Therapeutics Inc Dossier
Qualitative Analysis
Business overview
Indaptus Therapeutics, Inc. (Nasdaq: INDP) is a clinical-stage biotechnology company focused on developing a novel, systemically-administered anti-cancer and anti-viral immunotherapy platform. The company's patented technology leverages attenuated and killed, non-pathogenic, Gram-negative bacteria designed to safely stimulate both innate and adaptive immune responses. Its lead clinical candidate, Decoy20, is designed to produce single-agent activity and/or combination therapy-based durable responses in solid tumors (such as colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma) as well as chronic viral infections like hepatitis B (HBV) and HIV.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Following a change of control and recapitalization, the company has discontinued enrollment in its Decoy20 monotherapy and combination clinical trials. The primary strategic focus has shifted to identifying and executing a post-investment transaction, such as a merger or acquisition of an operating business.
Expected impact: Expected to transition the company away from its legacy biotechnology development model into a new operating business structure.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
The agreement was established to evaluate Decoy20 in combination with BeiGene's anti-PD-1 antibody, tislelizumab, for advanced solid tumors. However, following the strategic pivot in late 2025/early 2026, enrollment in this combination study was discontinued.
Terms: Indaptus was responsible for all clinical trial costs, while BeiGene agreed to provide tislelizumab at no cost.